title: Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study.
abstract: OBJECTIVE
  To assess the feasibility of using medroxyprogesterone acetate (MPA) and levonorgestrel intrauterine system (LNG-IUS) to treat early-stage endometrial cancer in young women who want to preserve their reproductive potential.
  
  
  METHODS
  Prospective observational study of 5 young patients (mean [SD] age, 38.4 [4.8] years; range, 33-41 years) with a grade 1 endometrial cancer that is presumably confined to the endometrium. The subjects were given a daily oral dose of 500 mg of MPA and LNG-IUS placement. They were followed with dilation and curettage every 3 months.
  
  
  RESULTS
  Complete remission was shown in 4 of 5 patients, and one patient showed partial remission. Biopsy results were negative in 2 patients at 3 months, in 1 patient at 6 months, and in 1 patient at 12 months. No treatment-related complications occurred. No recurrence was found during the follow-up period (mean [SD], 10.2 [3.6] months; range, 6-16 months).
  
  
  CONCLUSIONS
  The concomitant use of MPA with LNG-IUS is feasible for conservative treatment of early-stage endometrial cancer in young women who want to preserve their reproductive potential.
authors.affiliation: Department of Obstetrics and Gynecology, Gangnam CHA Medical Center, CHA University, Seoul, Korea.
authors.forename: Mi Kyung
authors.initials: MK
authors.lastname: Kim
authors.forename: Bo Sung
authors.initials: BS
authors.lastname: Yoon
authors.forename: Hyun
authors.initials: H
authors.lastname: Park
authors.forename: Seok Ju
authors.initials: SJ
authors.lastname: Seong
authors.forename: Hyun Hoon
authors.initials: HH
authors.lastname: Chung
authors.forename: Jae Weon
authors.initials: JW
authors.lastname: Kim
authors.forename: Soon Beom
authors.initials: SB
authors.lastname: Kang
mesh_terms: D000328:Adult; D000367:Age Factors; D000465:Algorithms; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D018269:Carcinoma, Endometrioid / Q000188:drug therapy*; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000517:prevention & control; D007436:Intrauterine Devices, Medicated / Q000009:adverse effects; D016912:Levonorgestrel / Q000008:administration & dosage* / Q000009:adverse effects; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D010865:Pilot Projects
chemical_list: D018931:Antineoplastic Agents, Hormonal; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate